Methods and compositions for modulating T helper (T H ) cell...

Details Methods and compositions for modulating T helper (T H ) cell... Methods and compositions for modulating T helper (T H ) cell...

2007-11-12

2010-06-08

Nickol, Gary B (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C424S085100, C514S012200, C514S002600, C530S351000

Reexamination Certificate

active

07731946

ABSTRACT:
Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.

REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5155027 (1992-10-01), Sledziewski et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5225539 (1993-07-01), Winter
patent: 5262564 (1993-11-01), Kun et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5516964 (1996-05-01), Umansky et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5567584 (1996-10-01), Sledziewski et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5750375 (1998-05-01), Sledziewski et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 5843725 (1998-12-01), Sledziewski et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6018026 (2000-01-01), Sledziewski et al.
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6291212 (2001-09-01), Sledziewski et al.
patent: 6291646 (2001-09-01), Sledziewski et al.
patent: 6300099 (2001-10-01), Sledziewski et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6406697 (2002-06-01), Capon et al.
patent: 6576744 (2003-06-01), Presnell et al.
patent: 7189400 (2007-03-01), Carter et al.
patent: 7198789 (2007-04-01), Carter et al.
patent: 7495085 (2009-02-01), Valge-Archer et al.
patent: 2002/0090680 (2002-07-01), Hodge
patent: 2002/0128446 (2002-09-01), Novak et al.
patent: 2002/0137677 (2002-09-01), Sprecher et al.
patent: 2003/0108549 (2003-06-01), Carter et al.
patent: 2004/0016010 (2004-01-01), Kasaian et al.
patent: 2006/0024268 (2006-02-01), Kasaian et al.
patent: 2006/0039902 (2006-02-01), Young et al.
patent: 2006/0159655 (2006-07-01), Collins et al.
patent: 2006/0257403 (2006-11-01), Young et al.
patent: 2008/0167241 (2008-07-01), Donaldson et al.
patent: 2008/0241098 (2008-10-01), Young et al.
patent: 0 812 913 (1997-12-01), None
patent: 1 088 831 (2001-04-01), None
patent: WO 93/08829 (1993-05-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 96/27011 (1996-09-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/20926 (1997-06-01), None
patent: WO 97/31946 (1997-09-01), None
patent: WO 97/33913 (1997-09-01), None
patent: WO 97/47741 (1997-12-01), None
patent: WO 97/47742 (1997-12-01), None
patent: WO 98/10638 (1998-03-01), None
patent: WO 98/11225 (1998-03-01), None
patent: WO 98/31811 (1998-07-01), None
patent: WO 99/47675 (1999-09-01), None
patent: WO 99/53049 (1999-10-01), None
patent: WO 00/08152 (2000-02-01), None
patent: WO 00/17235 (2000-03-01), None
patent: WO 00/27882 (2000-05-01), None
patent: WO 00/53761 (2000-09-01), None
patent: WO 01/85792 (2001-11-01), None
patent: WO 03/028630 (2003-04-01), None
patent: WO 2004/007682 (2004-01-01), None
patent: WO 2004/083249 (2004-09-01), None
patent: WO 2004/084835 (2004-10-01), None
patent: WO 2005/112983 (2005-12-01), None
patent: WO 2006/135385 (2006-12-01), None
patent: WO 2009/100035 (2009-08-01), None
Lazar et al, Mol. Cell. Biol, 1988, vol. 8, pp. 1247-1252.
“Amino Acid Comparison of Mouse and Human IL-21,” 3 pages, printed Aug. 4, 2009.
Parrish-Novak et al., Blast 2 Sequences Results comparing GenBank Accession Nos. Q9JHX3 and NP—068570, “Amino Acid Sequence comparison of Mouse and Human IL-21R,”, 2000.
Hatakeyama et al., Blast 2 Sequences Results comparing GenBank Accession Nos. NP—068570 and AAA59143, “Amino Acid Sequence comparison of Human IL-21R and Human IL-2Rβ,”, 1989.
Parrish-Novak et al., GenBank Accession No. Q9JHX3, “Interleukin-21 receptor precursor (IL-21R) (Mouse)” (2000).
Hatakeyama et al., GenBank Accession No. AAA59143, “Interleukin 2 receptor beta chain precursor peptide” (1998).
Parrish-Novak et al., GenBank Accession No. NP—068570, “Interleukin 21 receptor precursor [Homo sapiens]” (2000).
Davis et al., “Site Directed Mutagenesis,”Basic Methods in Molecular Biology, § 20-3, pp. 738-744 (2nded., Appleton & Lange, CT, 1994).
Gearing et al., “The International Standard for Human Interleukin-2,” J. Immunol. Meth., vol. 114, pp. 3-9 (1998).
Yokota et al., “Use of a cDNA Expression Vector for Isolation of Mouse Interleukin 2 cDNA Clones: Expression of T-Cell Growth-Factor Activity after Transfection of Monkey Cells,” Proc. Natl. Acad. Sci. USA., 82, (1), pp. 68-72 (1985).
Fukushima et al., “Interleukin-2 Carbohydrate Recognition Modulates CTLL-2 Cell Proliferation,” J. Biol. Chem., vol. 276, No. 10, pp. 7351-7356 (2001).
Wells, “Additivity of Mutational Effects in Proteins,” Biochemistry, vol. 29, No. 37, pp. 8509-8517 (Sep. 18, 1990).
Brenne et al., “Interleukin-21 is a growth and survival factor for human myeloma cells,” Blood, vol. 99, No. 10, pp. 3756-3762 (May 15, 2002).
Kasaian et al., “IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell Activation: A Mediator of the Transition from Innate to Adaptive Immunity,” Immunity, vol. 16, pp. 559-569 (2002).
Taylor, “The Classification of Amino Acid Conservation,” J. Theor. Biol., vol. 119, pp. 205-218 (1986).
Zvelebil et al., “Prediction of Protein Secondary Structure and Active Sites using the Alignment of Homologous Sequences,” J. Mol. Biol., vol. 195, pp. 957-961 (1987).
lwata et al., “A Broad-Spectrum Caspase Inhibitor Attenuates Allergic Airway Inflammation in Murine Asthma Model,” The Journal of Immunology, vol. 170, pp. 3386-3391 (2003).
Kinoshita et al., “Costimulation by B7-1 and B7-2 is Required for Autoimmune Disease in MRL-FaslprMice1,” J. Immunol., vol. 164, pp. 6046-6056 (2000).
Myers et al., “Collagen-Induced Arthritis, An Animal Model of Autoimmunity,” Life Sciences vol. 61, No. 19, pp. 1861-1878 (1997).
Heaney et al., “Soluble Receptorsd in Human Disease,” Journal of Leukocyte Biology, vol. 64, pp. 135-146 (Aug. 1998).
Mehta et al., “Biology of IL-21 and the IL-21 Receptor, Immunological Reviews,” vol. 202, pp. 84-95 (2004).
Bazan, “Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily,” Proc. Natl. Acad Sci. USA, vol. 87, pp. 6934-6938 (Sep. 1990).
Imler et al., “Identification of Three Adjacent Amino Acids of Interleukin-2 Receptor β Chain which Control the Affinity and the Specificity of the Interaction with Interleukin-2,” The EMBO Journal, vol. 11, No. 6, pp. 2047-2053 (1992).
LaRosa et al., “Amino Terminus of the Interleukin-8 Receptor Is a Major Determinant of Receptor Subtype Specificity,” The Journal of Biological Chemistry, vol. 267, No. 35, pp. 25402-25406 (1992).
Schimmenti et al., “Localization of an Essential Ligand Binding Determinant of the Human Erythropoietin Receptor to a Domain N-terminal to the WSXWS Motif: Implications for Soluble Receptor Function,” Experimental Hematology, vol. 23, pp. 1341-1346 (1995).
Mulhern et al., “The Solution Structure of the Cytokine-binding Domain of the Common β-Chain of the Receptors for Granulocyte-Macrophage Colony-stimulating Factor, Interleukin-3 and Interleukin-5,” J. Mol. Biol., vol. 297, pp. 989-1001

Affiliated with

Also associated with

Rating

Methods and compositions for modulating T helper (T H ) cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for modulating T helper (T H ) cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating T helper (T H ) cell... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4184813